FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of March 2026
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Notification of Admission of Shares
20
March 2026
Notification of Admission of Further Securities to Trading (PRM
1.6.4R)
AstraZeneca PLC (the Company) announced today the following
information in accordance with The Public Offers and Admissions to
Trading Regulations 2024 (POATRs) PRM 1.6.4R.
|
1
|
Details of the issuer
|
|
|
a)
|
Name
|
AstraZeneca PLC
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
2
|
Details of the transferable securities admitted to
trading
|
|
|
a)
|
Name, type and identification code
|
Ordinary Shares of $0.25 each
ISIN: GB0009895292
|
|
b)
|
Regulated market
|
London Stock Exchange - Main Market
|
|
c)
|
Number of further securities issued and admitted
|
45,750
|
|
d)
|
Total number of securities in issue following
admission
|
1,550,980,332
|
|
e)
|
Fungibility
|
Fully fungible with existing Ordinary Shares
|
|
3
|
Admission details
|
|
|
a)
|
Date of admission
|
Issued between 20 January 2026 to 19 March 2026 (admitted under a
block admission dated 29
January 2021)
|
|
b)
|
Prospectus information
|
Prospectus: N/A
Supplementary: N/A
Company's webpage: https://www.astrazeneca.com
|
|
c)
|
Coverage of notification
|
Admission of shares under the Company's employee share schemes from
20 January 2026 up to 19 March 2026, admitted to trading on the
Main Market of the London Stock Exchange under the Company's
existing block admission of shares dated 29 January
2021.
|
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date: 20 March 2026
|
|
By: /s/
Matthew Bowden
|
|
|
Name:
Matthew Bowden
|
|
|
Title:
Company Secretary
|